IL-12 | Jotup

OncoNano Medicine Presents Preclinical Data for ON-BOARD™ IL-12 Program at AACR Annual Meeting 2024

Retrieved on:

Wednesday, April 10, 2024

Despite its potent pleiotropic and well-established anti-cancer effects, the clinical application of IL-12 has been hindered by significant adverse toxicities.

Key Points:

Despite its potent pleiotropic and well-established anti-cancer effects, the clinical application of IL-12 has been hindered by significant adverse toxicities.
OncoNano developed ON-BOARD™, an ultra-pH sensitive nanoparticle platform, to shield payloads from systemic exposure and target solid tumors by responding to the highly acidic tumor microenvironment.
Findings also reveal that ONM-412 illustrates favorable stability and pH-responsive IL-12 bioactivity in vitro,” said Tian Zhao, Ph.D., Vice President of Research and Development for OncoNano Medicine.
Link to the poster may be found on the OncoNano Medicine website at: News - OncoNano Medicine .

Mural Oncology Presents Preclinical Data for IL-18 and IL-12 Programs at the 2024 American Association for Cancer Research Annual Meeting

Retrieved on:

Tuesday, April 9, 2024

Toxicity, Half-life, Patient, Tumor microenvironment, Observation, Interleukin 18, AACR, Neoplasm, Cancer, Cytokine, Immune system, IL-12, Vaccine

WALTHAM, Mass and DUBLIN, Ireland, April 09, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today shared poster presentations with pre-clinical data from its Interleukin-18 (IL-18) and IL-12 programs at the American Association for Cancer Research (AACR) annual meeting taking place April 5-10 in San Diego, California. This is the first time Mural has shared findings from either program. The details for the presentations are as follows, and both posters are available at https://www.muraloncology.com/publications/.

Key Points:

Mural’s protein engineering approach is twofold: first, it introduces mutations to IL-18 that are designed to minimally impact the structure while eliminating binding to IL-18BP.
The optimal balance of potency and pharmacokinetic enhancement is still being determined to nominate a lead IL-18 development candidate.
We show that resistance to IL-18BP combined with the drug’s extended half-life leads to a durable immunological effect in preclinical models.
“We believe that by self-assembling the split IL-12 subunits within the tumor microenvironments, we can circumvent native IL-12’s severe toxicities without compromising its efficacy.

Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing

Retrieved on:

Thursday, March 28, 2024

WALTHAM, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that it has entered into a securities purchase agreement with certain existing accredited investors, including Bain Capital Life Sciences and Rock Springs Capital, to issue and sell an aggregate of 1,953,125 shares of Xilio common stock at a price of $0.64 per share and prefunded warrants to purchase up to an aggregate of 15,627,441 shares of Xilio common stock at a purchase price of $0.6399 per prefunded warrant share, through a private investment in public equity financing. The prefunded warrants will have an exercise price of $0.0001 per share of common stock, be immediately exercisable and remain exercisable until exercised in full. Xilio anticipates receiving aggregate gross proceeds from the private placement of approximately $11.3 million, before deducting placement agent fees and expenses payable by the company. The private placement is expected to close on April 2, 2024, subject to the satisfaction of customary closing conditions. Xilio expects to use the proceeds from the private placement to fund working capital and other general corporate purposes.

Key Points:

Xilio anticipates receiving aggregate gross proceeds from the private placement of approximately $11.3 million, before deducting placement agent fees and expenses payable by the company.
The private placement is expected to close on April 2, 2024, subject to the satisfaction of customary closing conditions.
Xilio expects to use the proceeds from the private placement to fund working capital and other general corporate purposes.
Prior to the potential transition fee, Xilio is eligible to receive up to a total of $29.0 million in additional equity investments and a development milestone payment.

Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program

Retrieved on:

Thursday, March 28, 2024

Molecule, Therapeutic index, EPS, Gilead Sciences, Patient, Pharming, Tumor microenvironment, Doctor of Philosophy, MD, Senior, IPR, Investment, Therapy, Antibody, Cytokine, IL-12, Pharmaceutical industry

FOSTER CITY, Calif. and WALTHAM, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Gilead Sciences, Inc. (Nasdaq: GILD) and Xilio Therapeutics, Inc. (Nasdaq: XLO) today announced an exclusive license agreement to develop and commercialize Xilio’s Phase 1 tumor-activated IL-12 program, XTX301.

Key Points:

-- Gilead Granted Exclusive License to Xilio’s Tumor-Activated IL-12 Program, Including XTX301, a Clinical-Stage IL-12 Molecule with Potential to Treat a Broad Range of Cancers --
FOSTER CITY, Calif. and WALTHAM, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Gilead Sciences, Inc. (Nasdaq: GILD) and Xilio Therapeutics, Inc. (Nasdaq: XLO) today announced an exclusive license agreement to develop and commercialize Xilio’s Phase 1 tumor-activated IL-12 program, XTX301.
XTX301 is currently being evaluated in a Phase 1 dose escalation trial in patients with advanced solid tumors.
Xilio will receive $43.5 million in upfront payments, including a cash payment of $30.0 million and an initial equity investment by Gilead of $13.5 million in Xilio common stock at a premium.
Xilio will be responsible for conducting clinical development of XTX301 in the ongoing Phase 1 clinical trial through dose expansion.

PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results

Retrieved on:

Wednesday, March 27, 2024

This decision enables PDS Biotech to focus its resources on the drug regimen it believes has the highest potential to benefit patients with HNSCC and to drive shareholder value.

Key Points:

This decision enables PDS Biotech to focus its resources on the drug regimen it believes has the highest potential to benefit patients with HNSCC and to drive shareholder value.
“We have had several discussions with key opinion leaders in HNSCC regarding the use of the triple combination in HNSCC.
The NCI clinical trial data show significant promise in the use of PDS01ADC in combination with Versamune® HPV,” said Katharine A.
The event will be archived on the Investor Relations section of PDS Biotech’s website for six months.

Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program

Retrieved on:

Thursday, March 28, 2024

Gilead Sciences, Inc. (Nasdaq: GILD) and Xilio Therapeutics, Inc. (Nasdaq: XLO) today announced an exclusive license agreement to develop and commercialize Xilio’s Phase 1 tumor-activated IL-12 program, XTX301.

Key Points:

Gilead Sciences, Inc. (Nasdaq: GILD) and Xilio Therapeutics, Inc. (Nasdaq: XLO) today announced an exclusive license agreement to develop and commercialize Xilio’s Phase 1 tumor-activated IL-12 program, XTX301.
View the full release here: https://www.businesswire.com/news/home/20240328734624/en/
Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies.
Xilio will receive $43.5 million in upfront payments, including a cash payment of $30 million and an initial equity investment by Gilead of $13.5 million in Xilio common stock at a premium.
Xilio will be responsible for conducting clinical development of XTX301 in the ongoing Phase 1 clinical trial through dose expansion.

Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Retrieved on:

Monday, February 26, 2024

Research, Investment, Form 10-K, Sale, Form, HSV, Society, KRYS, Immunotherapy, Trial of the century, Genotype, Eye, PI, Krystal, Transgene, European Medicines Agency, Security (finance), Pharmacology, NCT, DEB, Jeune, ID, ODD, AATD, Safety, Survival, Medicaid, IND, Bronchoscopy, IL-12, Gene, MAA, FDA, Patent, Priority review, Cell, Lung, Patient, Medicine, Pharmaceutical industry

(the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today reported financial results and key business updates for the fourth quarter and year ending December 31, 2023.

Key Points:

(the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today reported financial results and key business updates for the fourth quarter and year ending December 31, 2023.
Financial results for the quarter ended December 31, 2023:
Cash, cash equivalents, and investments totaled $594.1 million on December 31, 2023.
The Company recorded net product revenue of $42.1 million from sales of VYJUVEK during the quarter ended December 31, 2023.
For additional information on the Company’s financial results for the year ended December 31, 2023, please refer to the Form 10-K filed with the Securities and Exchange Commission.

Bonum Therapeutics to Present Poster on Lead Program at AACR 2024

Retrieved on:

Tuesday, March 5, 2024

Scientists from Bonum will present these data in a poster at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10 in San Diego, CA.

Key Points:

Scientists from Bonum will present these data in a poster at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10 in San Diego, CA.
The in vivo safety and efficacy data described in the poster demonstrate that this program is suitable for progressing into the clinic.
John Mulligan, PhD, Bonum Therapeutics’ CEO, commented, “We are excited with the progress of our lead program, cLAG3-IL2, and are eager to make the first public presentation about the program at AACR.”
The poster will be available on the Bonum website on the day of the presentation.
The merits of the platform were validated by the Roche acquisition of Good Therapeutics and its PD-1-regulated IL-2 program in September 2022.

Mural Oncology Launches to Advance Pipeline of Novel Engineered Cytokine Immunotherapies

Retrieved on:

Wednesday, November 15, 2023

DUBLIN, Ireland, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA) today launched as an independent, publicly traded, clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation and protein engineering to develop novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Mural’s ordinary shares will begin trading on the Nasdaq Global Market tomorrow, November 16th, under the ticker symbol “MURA”.

Key Points:

“Immunotherapies have made a tremendous impact on the treatment of cancers over the past decade,” said Caroline Loew, Ph.D., the Company’s chief executive officer.
We believe Mural Oncology can lead the future of immunotherapies for patients.
Our protein engineering expertise allows us to reimagine the development of pro-inflammatory cytokine-based therapeutics that could address the key limitations with current cancer immunotherapies.
Goodwin Procter LLP and Arthur Cox LLP are serving as legal counsel to Mural Oncology.

Ankyra Therapeutics Announces Pre-Clinical Research Published in December JCI Insight Demonstrating Potent Anti-Tumor Activity of Anchored IL-12 in Multiple Murine Cancer Models

Retrieved on:

Tuesday, December 12, 2023

Ankyra Therapeutics, an emerging clinical-stage biotechnology company pioneering anchored immunotherapies to treat cancer, today announced results from a preclinical study demonstrating potent anti-tumor activity of its lead program ANK-101 were published in the December issue of the Journal of Clinical Investigation Insight (JCI Insight).

Key Points:

Ankyra Therapeutics, an emerging clinical-stage biotechnology company pioneering anchored immunotherapies to treat cancer, today announced results from a preclinical study demonstrating potent anti-tumor activity of its lead program ANK-101 were published in the December issue of the Journal of Clinical Investigation Insight (JCI Insight).
The research paper is titled “Intratumoral aluminum hydroxide-anchored IL-12 drives potent antitumor activity by remodeling the tumor microenvironment.”
ANK-101 is a novel tumor-directed anchored immune medicine (AIM) composed of interleukin-12 (IL-12) linked to aluminum hydroxide.
“Our pre-clinical data indicates that anchored immunotherapy retains active IL-12 at the tumor site for weeks, versus just hours with unanchored recombinant IL-12.
This results in potent immune activation with limited systemic exposure, indicating the potential to improve patient outcomes while reducing side effects.